(BBRE) JPMorgan BetaBuilders MSCI - Ratings and Ratios
Exchange: BATS • Country: USA • Currency: USD • Type: Etf • ISIN: US46641Q7381 • Real Estate
BBRE: Real, Estate, Investment, Trust, Securities
The JPMorgan BetaBuilders MSCI US REIT ETF (BBRE) is designed for investors seeking exposure to the U.S. real estate investment trust (REIT) market. It invests at least 80% of its assets in securities from the MSCI US REIT Index, which is a market-capitalization-weighted index. This means larger REITs have a greater influence on the funds performance. The index is free-float adjusted, ensuring that only publicly available shares are considered, which can lead to a more accurate representation of market conditions.
The funds use of up to 20% of its assets in exchange-traded futures is a strategic move to enhance tracking of the underlying index. This approach allows for efficient portfolio management and can help in maintaining alignment with the indexs performance, which is crucial for investors looking for consistent returns. The MSCI US REIT Index itself is a well-known benchmark, tracking the performance of U.S. equity REITs, which are companies that own, develop, and manage income-generating real estate properties.
For fund managers and investors, understanding the structure of BBRE is key. The ETF offers diversification across various real estate sectors, including residential, commercial, and industrial properties. This diversification can mitigate risk and provide a broad exposure to the real estate market without the need for direct property investment. The funds market-cap weighting means that larger, more established REITs will have a greater impact on its performance, which can be both a stabilizing and growth-oriented feature.
Key details about the fund include its significant assets under management (AUM) of $931.88 million, which speaks to its liquidity and investor confidence. While traditional valuation metrics like P/E and P/B are not directly applicable to REITs due to their unique financial structures, the funds structure allows it to capture the essence of the REIT markets performance effectively. This makes it a valuable tool for those looking to integrate real estate exposure into their portfolios.
Additional Sources for BBRE ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BBRE ETF Overview
Market Cap in USD | 956m |
Category | Real Estate |
TER | 0.11% |
IPO / Inception | 2018-06-15 |
BBRE ETF Ratings
Growth 5y | 46.7% |
Fundamental | - |
Dividend | 55.9% |
Rel. Strength Industry | 1.41 |
Analysts | - |
Fair Price Momentum | 92.23 USD |
Fair Price DCF | - |
BBRE Dividends
Dividend Yield 12m | 3.14% |
Yield on Cost 5y | 4.42% |
Annual Growth 5y | 3.50% |
Payout Consistency | 94.7% |
BBRE Growth Ratios
Growth Correlation 3m | 6.9% |
Growth Correlation 12m | 72.4% |
Growth Correlation 5y | 54% |
CAGR 5y | 7.77% |
CAGR/Max DD 5y | 0.22 |
Sharpe Ratio 12m | 0.73 |
Alpha | 3.37 |
Beta | 0.64 |
Volatility | 15.67% |
Current Volume | 17.6k |
Average Volume 20d | 19.6k |
As of March 06, 2025, the stock is trading at USD 98.23 with a total of 17,586 shares traded.
Over the past week, the price has changed by +1.58%, over one month by +2.71%, over three months by -0.48% and over the past year by +15.46%.
Partly, yes. Based on ValueRay Analyses, JPMorgan BetaBuilders MSCI (BATS:BBRE) is currently (March 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 46.74 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BBRE as of March 2025 is 92.23. This means that BBRE is currently overvalued and has a potential downside of -6.11%.
JPMorgan BetaBuilders MSCI has no consensus analysts rating.
According to ValueRays Forecast Model, BBRE JPMorgan BetaBuilders MSCI will be worth about 106.3 in March 2026. The stock is currently trading at 98.23. This means that the stock has a potential upside of +8.25%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 106.3 | 8.2% |